Next Science Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXSCF research report →
Companywww.nextscience.com
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections.
- CEO
- Matthew Franco Myntti
- IPO
- 2021
- HQ
- Sydney, NSW, AU
Price Chart
Valuation
- Market Cap
- $292.63K
- P/E
- -4.27
- P/S
- 1.80
- P/B
- -54.38
- EV/EBITDA
- -5.62
- Div Yield
- 100.00%
Profitability
- Gross Margin
- 82.27%
- Op Margin
- -39.25%
- Net Margin
- -42.13%
- ROE
- -491.26%
- ROIC
- -135.01%
Growth & Income
- Revenue
- $22.82M · 2.87%
- Net Income
- $-10,586,018 · 56.81%
- EPS
- $-0.04 · 47.77%
- Op Income
- $-10,304,109
- FCF YoY
- 46.36%
Performance & Tape
- 52W High
- $0.11
- 52W Low
- $0.00
- 50D MA
- $0.06
- 200D MA
- $0.06
- Beta
- 1.69
- Avg Volume
- 4.23K
Get TickerSpark's AI analysis on NXSCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NXSCF Coverage
We haven't published any research on NXSCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NXSCF Report →